ADIPOQ and metabolic syndrome: After adjusting for the effects of age and gender, the results revealed apM1 +45 TT carriers with fasting plasma glucose greater than 100 mg/dL (OR = 7.59, 95% CI 3.69-15.63), and apM1 +45 GG/GT carriers with fasting plasma glucose greater than 100 mg/dL (OR = 5.86, 95% CI 2.79-12.32) had significantly higher risks of MetS than apM1+45 GG/GT carriers with fasting plasma glucose less than 100 mg/dL.